ExodusPoint Capital Management LP Takes $402,000 Position in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)

ExodusPoint Capital Management LP acquired a new position in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 106,237 shares of the company's stock, valued at approximately $402,000. ExodusPoint Capital Management LP owned approximately 0.15% of Amylyx Pharmaceuticals as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Blue Trust Inc. lifted its position in Amylyx Pharmaceuticals by 232.1% during the 4th quarter. Blue Trust Inc. now owns 6,987 shares of the company's stock worth $26,000 after buying an additional 4,883 shares in the last quarter. Fox Run Management L.L.C. bought a new position in Amylyx Pharmaceuticals in the fourth quarter valued at approximately $45,000. EntryPoint Capital LLC acquired a new position in shares of Amylyx Pharmaceuticals during the 4th quarter worth approximately $53,000. Y Intercept Hong Kong Ltd acquired a new stake in shares of Amylyx Pharmaceuticals in the 4th quarter valued at approximately $56,000. Finally, American Century Companies Inc. grew its stake in shares of Amylyx Pharmaceuticals by 181.8% in the fourth quarter. American Century Companies Inc. now owns 59,310 shares of the company's stock valued at $224,000 after buying an additional 38,261 shares in the last quarter. Institutional investors and hedge funds own 95.84% of the company's stock.

Analyst Ratings Changes

AMLX has been the subject of several recent analyst reports. Mizuho upgraded shares of Amylyx Pharmaceuticals from a "neutral" rating to an "outperform" rating and raised their target price for the company from $3.00 to $7.00 in a research note on Monday, April 7th. HC Wainwright reaffirmed a "buy" rating and set a $12.00 price target on shares of Amylyx Pharmaceuticals in a research report on Wednesday, March 5th. Two analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Amylyx Pharmaceuticals has a consensus rating of "Moderate Buy" and an average price target of $8.00.

Insider Activity at Amylyx Pharmaceuticals

In related news, CEO Joshua B. Cohen sold 21,490 shares of Amylyx Pharmaceuticals stock in a transaction that occurred on Monday, March 31st. The shares were sold at an average price of $3.47, for a total value of $74,570.30. Following the sale, the chief executive officer now owns 3,355,280 shares of the company's stock, valued at approximately $11,642,821.60. The trade was a 0.64 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Bernhardt G. Zeiher acquired 10,000 shares of the business's stock in a transaction that occurred on Thursday, March 20th. The stock was acquired at an average cost of $3.70 per share, with a total value of $37,000.00. Following the completion of the acquisition, the director now owns 10,000 shares in the company, valued at $37,000. This trade represents a ∞ increase in their position. The disclosure for this purchase can be found here. Over the last three months, insiders sold 64,509 shares of company stock valued at $222,586. 11.70% of the stock is owned by insiders.

Amylyx Pharmaceuticals Stock Up 4.2 %

Shares of AMLX stock traded up $0.16 during trading hours on Friday, reaching $3.98. The company's stock had a trading volume of 724,313 shares, compared to its average volume of 1,284,983. Amylyx Pharmaceuticals, Inc. has a fifty-two week low of $1.58 and a fifty-two week high of $7.27. The company has a market capitalization of $352.64 million, a price-to-earnings ratio of -1.04 and a beta of -0.53. The firm's 50 day simple moving average is $3.55 and its 200-day simple moving average is $4.09.

Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) last issued its quarterly earnings data on Tuesday, March 4th. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.06). The business had revenue of ($0.67) million during the quarter. Sell-side analysts predict that Amylyx Pharmaceuticals, Inc. will post -2.2 earnings per share for the current year.

Amylyx Pharmaceuticals Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.